Form 4: Amylyx Pharmaceuticals Director Paul Fonteyne Acquires 25,000 Stock Options

Paul R. Fonteyne, a Director at Amylyx Pharmaceuticals, Inc. (AMLX), has acquired 25,000 stock options with an exercise price of $5.05, set to vest by June 2026.

Summary

• Paul R. Fonteyne, a Director of Amylyx Pharmaceuticals, Inc. (AMLX), acquired 25,000 stock options.
• The transaction date for this acquisition was June 5, 2025.
• The exercise price for these stock options is $5.05 per share.
• The options are set to expire on June 4, 2035.
• The shares subject to this option will vest in full upon the earlier of June 5, 2026, or the date of the next annual meeting, contingent on Mr. Fonteyne's continuous service to the Issuer through the vesting date.
• Following this transaction, Mr. Fonteyne beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing indicates a routine equity compensation grant to an existing director. This is a neutral event but can be viewed as slightly positive as it reinforces the director's alignment with the company's long-term performance.

Positives

• The acquisition of stock options by a director aligns their financial interests with the long-term performance and shareholder value of Amylyx Pharmaceuticals.
• This grant is a standard component of director compensation, indicating continued commitment and incentivization for the director's service.

Future Outlook

The vesting schedule of the stock options, contingent on continuous service, implies an expectation of the director's ongoing involvement with the company through at least June 2026.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice in the pharmaceutical and biotechnology industries to attract and retain experienced board members and align their interests with long-term company success.

Comparison to Industry Standards

• Granting stock options to directors is a widely accepted compensation practice across the pharmaceutical and biotech sectors, similar to how companies like Biogen Inc. or Moderna, Inc. incentivize their board members.
• This practice aims to align the director's financial incentives with the company's stock performance, fostering a long-term perspective on strategic decisions and shareholder value creation.

Related Party Transactions

• The transaction involves the grant of stock options to Paul R. Fonteyne, a Director of Amylyx Pharmaceuticals, Inc., which constitutes a compensation-related transaction with a related party.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest according to the specified schedule (earlier of June 5, 2026, or the next annual meeting, subject to continuous service).
• Upon vesting, the director will have the right to exercise these options at the stated price of $5.05 per share until the expiration date of June 4, 2035.

Key Dates

Recommendation

Keywords

Amylyx Pharmaceuticals, AMLX, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Pharmaceuticals, Biotech